333 related articles for article (PubMed ID: 27484749)
1. Management of Juvenile Idiopathic Arthritis: A Clinical Guide.
Blazina Š; Markelj G; Avramovič MZ; Toplak N; Avčin T
Paediatr Drugs; 2016 Dec; 18(6):397-412. PubMed ID: 27484749
[TBL] [Abstract][Full Text] [Related]
2. Biologics in juvenile idiopathic arthritis: a narrative review.
Vanoni F; Minoia F; Malattia C
Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
[TBL] [Abstract][Full Text] [Related]
3. Update on the treatment of juvenile idiopathic arthritis.
Harris JG; Kessler EA; Verbsky JW
Curr Allergy Asthma Rep; 2013 Aug; 13(4):337-46. PubMed ID: 23605168
[TBL] [Abstract][Full Text] [Related]
4. Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.
Pagnini I; Bertini F; Cimaz R
Paediatr Drugs; 2016 Apr; 18(2):101-8. PubMed ID: 26939782
[TBL] [Abstract][Full Text] [Related]
5. Juvenile Idiopathic Arthritis.
Barut K; Adrovic A; Şahin S; Kasapçopur Ö
Balkan Med J; 2017 Apr; 34(2):90-101. PubMed ID: 28418334
[TBL] [Abstract][Full Text] [Related]
6. Treatment of juvenile idiopathic arthritis: a revolution in care.
Stoll ML; Cron RQ
Pediatr Rheumatol Online J; 2014; 12():13. PubMed ID: 24782683
[TBL] [Abstract][Full Text] [Related]
7. The use of methotrexate in children with rheumatic diseases.
Gutiérrez-Suárez R; Burgos-Vargas R
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S122-7. PubMed ID: 21044445
[TBL] [Abstract][Full Text] [Related]
8. The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.
Hügle B; Horneff G
Expert Opin Pharmacother; 2016; 17(5):703-14. PubMed ID: 26678914
[TBL] [Abstract][Full Text] [Related]
9. [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)].
Bukovac LT; Vidović M; Lamot L; Perica M; Harjacek M;
Reumatizam; 2013; 60(1):57-66. PubMed ID: 24003687
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.
Zamora-Legoff JA; Krause ML; Crowson CS; Muskardin TW; Mason T; Matteson EL
Clin Rheumatol; 2016 Jun; 35(6):1493-9. PubMed ID: 26825065
[TBL] [Abstract][Full Text] [Related]
11. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.
Gieling J; van den Bemt B; Hoppenreijs E; Schatorjé E
Pediatr Rheumatol Online J; 2022 Dec; 20(1):109. PubMed ID: 36471348
[TBL] [Abstract][Full Text] [Related]
13. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.
Halyabar O; Mehta J; Ringold S; Rumsey DG; Horton DB
Paediatr Drugs; 2019 Dec; 21(6):469-492. PubMed ID: 31673960
[TBL] [Abstract][Full Text] [Related]
14. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
15. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
[TBL] [Abstract][Full Text] [Related]
16. Ovarian reserve in children with juvenile idiopathic arthritis using biologic disease-modifying anti-rheumatic drugs.
Ozer Y; Yildiz M; Turan H; Tarcin G; Bingol Aydin D; Gunalp A; Haslak F; Kilic Konte E; Aslan E; Koker O; Bayramoglu E; Sahin S; Adrovic A; Barut K; Kasapcopur O; Evliyaoglu O
Clin Rheumatol; 2024 Jan; 43(1):399-406. PubMed ID: 37646858
[TBL] [Abstract][Full Text] [Related]
17. Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis.
Buckley L; Ware E; Kreher G; Wiater L; Mehta J; Burnham JM
J Rheumatol; 2020 Feb; 47(2):273-281. PubMed ID: 31308202
[TBL] [Abstract][Full Text] [Related]
18. Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry.
Thiele F; Klein A; Windschall D; Hospach A; Foeldvari I; Minden K; Weller-Heinemann F; Horneff G
Rheumatol Int; 2021 Apr; 41(4):751-762. PubMed ID: 33590331
[TBL] [Abstract][Full Text] [Related]
19. Judicious use of biologicals in juvenile idiopathic arthritis.
Zhao Y; Wallace C
Curr Rheumatol Rep; 2014 Nov; 16(11):454. PubMed ID: 25218736
[TBL] [Abstract][Full Text] [Related]
20. Rheumatoid factor value for determining the first biologic agent to use for non-systemic juvenile idiopathic arthritis.
Yamasaki Y; Nakamura A; Kubota T; Mitsunobu T; Moriyama M; Takei S; Okamoto Y
Mod Rheumatol; 2023 Nov; 33(6):1171-1175. PubMed ID: 36197747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
